Novavax shares plunge after COVID-19 vaccine maker raises doubts over its future
Novavax — whose COVID-19 vaccine is its only marketed product after 35 years in business — on Tuesday flagged significant uncertainty around its 2023 revenue. Go to Source 01/03/2023 – 18:03 / Twitter: @hoffeldtcom